Menorrhagia 2.5-10 mg/day for 5-10 days on days 16-21 of the menstrual cycle. Repeat for 2 cycles.
Mild to moderate endometriosis 10 mg 3 times/day.
As progestogen component in menopausal HRT Dosage depends on estrogen component of therapy, several regimens are used: 1.5 mg, 2.5 mg or 5 mg/day; 5 or 10 mg/day for 12-14 days of a 28-day cycle; 20 mg/day for 14 days of a 91-day cycle.
Breast cancer 0.4-1.5 g/day. Max: 2 g/day.
Palliation of endometrial and renal carcinoma 200-600 mg/day.
Palliation of prostatic carcinoma 100-600 mg/day.
Secondary amenorrhea 2.5-10 mg/day for 5-10 days. Repeat for 3 cycles.
Endometriosis 50 mg/wk.
Contraception 150 mg 12 wkly.
Breast cancer 0.5-1 g/day for 1st 4 wk. Maintenance 0.5 g twice wkly.
Palliation of endometrial and renal carcinoma Initial: 0.4-1 g/wk. Reduce if needed; maintenance may be as low as 0.4 g/mth.
Palliation of prostatic carcinoma 0.5 g twice wkly for 1st 3 mth. Maintenance: 0.5 g/wk.
Contraception; Endometriosis 104 mg 12-14 wkly.
Adverse drug reactions
: Depression, fluid retention. Fatigue, insomnia, dizziness, headache, nausea; breast tenderness; weight gain/loss, anorexia; cholestatic jaundice; pain at injection site. Potentially fatal: thrombophlebitis and pulmonary embolism.
Adapted from CIMS Drug Information System. Internet. Accessed on June 16, 2016.